RGBP News and Press, Regen BioPharma Inc

Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments PR Newswire SAN DIEGO , Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing sev...

Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program PR Newswire SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic ( http...

Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program PR Newswire Autoimmunity to be Targeted SAN DIEGO , Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) ...

Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly PR Newswire SAN DIEGO , Oct. 18, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels...

PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness...

Regen BioPharma, Inc. Receives First Phase of Confirmatory Study PR Newswire CAR-T Cells Created SAN DIEGO , Oct. 10, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of...

BALTIMORE, MD / ACCESSWIRE / October 4, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Regen BioPharma, Inc. (OTCPK:RGBP). Leveraging its deep IP and surprising r...

Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies PR Newswire Initial Design and Testing Complete SAN DIEGO , Sept. 19, 2023...

Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio PR Newswire Company Expands on Issued Patent to Create Novel Approach to Selectively Killing Tumor Cells SAN DIEGO , Jan. 20, 2023 /PRNewswire/ -- Regen ...

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer PR Newswire SAN DIEGO , Dec. 19, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to hig...